Monopar Therapeutics Inc. (MNPR)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-14) · 99.1 | ||
| 10-K/A | FY-2025 | |||
| 10-KLatest | FY-2025 | 8-K (2026-03-27) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-31) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-08) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-09) · 99.1 · 99.2 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-09) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-28) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-10) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Consolidated Balance Sheets | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Consolidated Balance Sheets (P) | ||
| Condensed Consolidated Statements of Operations and Comprehensive Income (loss) (unaudited) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders' Equity (P) | ||
| Notes | ||
| Award Timing Disclosure | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Note 1 | ||
| Note 10 | — |
|
| Note 2 | ||
| Note 3 | ||
| Note 4 | ||
| Note 5 | ||
| Note 6 | ||
| Note 7 | ||
| Note 8 | ||
| Note 9 | ||